530 KB18 KB192920262012Drnovšek-Olup, BrigitaLavrič, Alenkaletnik:81str. I-83-I-88številka:supl.ISSN:1318-0347COBISSID:294316URN:URN:NBN:SI:doc-LMJO0IMAslSlovensko zdravniško društvoZdravniški vestnikanti-VEGFbevacizumabpterigijvaskularizacijaUčinek podvezničnega bevacizumaba na pterigij| Efficiency of subconjunctival bevacizumab on pterygium|Background: To evaluate the effect and complications of subconjunctival bevacizumab (Avastin Ž) on primary and recurrent pterygium. Methods: This prospective study included sixteen patients with pterygium, who received subconjunctival injection of bevacizumab (1.25 mg/0,1 mL). Digital photographywas used to evaluate vascularization of pterygium at 1 week, 1 month and 6 months after injection. Results: Sixteen patients (9 men and 7 women), aged between 41 and 74 years, with pterygium were included in the study. The pterygium was primary in nine patients and recurrent in seven patients. A rapid regression of vascularisation of pterygium was noted one week after treatment in all patients treated with bevacizumab. The recurrence was observed in two patients 1 month and in ten patients 6 months after injection. No change of visual acuity was noted and no systemic or ocular adverse events were observed. Conclusions: Subconjunctival bevacizumab (AvastinŽ) was safe and effective in providing a short-term regression of conjunctival vessels in the pterygial bedIzhodišča: Oceniti učinek in zaplete podvezničnega bevacizumaba (AvastinŽ) na primarni in ponavljajoči se pterigij. Metode: Prospektivna študija je vključevala 16 bolnikov s pterigijem, ki so prejeli injekcijo bevacizumaba podočesno veznico (1,25 mg/0,1 mL). Ožiljenost pterigija 1 teden, 1 mesec in 6mesecev po injekciji smo ocenili s primerjavo digitalnih fotografij. Rezultati: V študijo je bilo vključenih 16 bolnikov s pterigijem (9 moških in 7 žensk), starih med 41 in 74 let. Pterigij je bil primaren pri devetih bolnikih in ponavljajoči se pri 7 bolnikih. Pri vseh bolnikih, zdravljenih z bevacizumabom, smo opazili hitro pojenjanje ožiljenosti pterigija en teden po zdravljenju. Ponovitev vaskularizacije smo opazili pri dveh bolnikih 1 mesec in pri desetih bolnikih 6 mesecev po injekciji. Sprememb v vidni ostrini, sistemskih ali očesnih škodljivih učinkov nismo opazili. Zaključki: Podveznični bevacizumab (AvastinŽ) je bil varen in učinkovit pri kratkotrajni regresiji vezničnih žilic v pterigijuTEXTznanstveno časopisjejournalsSlovenian National E-content AggregatorNational and University Library of SloveniaSlovensko zdravniško društvo